Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

Comment by LithLoveron May 28, 2021 3:24pm
67 Views
Post# 33287907

RE:RE:RE:RE:From the management circular

RE:RE:RE:RE:From the management circularThe 8:1 was planned for the Nasdaq but I think they got talked into by the institutional investors and analysts looking to move the share price over $1 to encourage buying.  

As it turned out we still don't have the exposure to the US market as Jack Lifton just mentioned in the interview with Tripp.

Had they moved to a US exchange first , increased marketing and partnered with the investors/analysts and than the 8:1 r/s might be a differnt story but thats in the past.

They need to:

1) Increase Marketing.
2) list on a OTC US exchange and gain more exposure to help move the SP to $2 or more
3) Once over $2 do the r/s and move to Nasdaq 



 
Mermer2328 wrote:
Its all fine and dandy and I really hope that in the next yr the 2 for 1 splitt will have the SP high enough to trade on the Nazdaq. But this was the same story for doing an 8 to 1 reverse split. so that went from 9 cents to 72.. Where are we now??? All talk. no action. that's what needs to change


<< Previous
Bullboard Posts
Next >>